Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly.
Open FlipIndia's infrastructure, banking, and financial services sectors are poised for rapid growth in 2025, driven by government investments and rising demand. FMCG, quick commerce, cement, transmission, and defence sectors also offer promising investment opportunities, while green energy and data centers emerge as key areas for sustainable growth.
Open FlipOn Thursday, Benchmark indices concluded the trading day on a flat note as Sensex closed at 78,472.48, while Nifty closed up by 0.10% and closed at 23,750.20 level. Market volatility, as indicated by India VIX, rose by 6.53%. Top 3 price-volume breakout stocks: 💰Intellect Design Arena, 💰Niva Bupa Health Insurance Company, 💰Garuda Construction and Engineering.
Open Flip